Sign In
Buy GNOM
$49.01
+0.96 (+1.99%)
At Close: Jun 03, 2026
Beyond Tech Industry: Here's how Biotech ETFs Are Riding the AI Wave
10:42am, Monday, 16'th Mar 2026
IBB and other biotech ETFs are gaining traction as AI reshapes drug discovery, genomics, and clinical trials, giving investors diversified exposure to biotech innovation.
Comprehensive Money Management Services LLC Reduces Position in Global X Genomics & Biotechnology ETF $GNOM
04:54am, Saturday, 10'th Jan 2026
Comprehensive Money Management Services LLC decreased its position in shares of Global X Genomics and Biotechnology ETF (NASDAQ: GNOM) by 74.4% during the undefined quarter, according to the company i
Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Crosses Above 200-Day Moving Average – Should You Sell?
03:16am, Wednesday, 07'th Jan 2026
Global X Genomics and Biotechnology ETF (NASDAQ: GNOM - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $40.
Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Passes Above 200-Day Moving Average – Here’s Why
02:38am, Wednesday, 03'rd Dec 2025
Shares of Global X Genomics and Biotechnology ETF (NASDAQ: GNOM - Get Free Report) crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $37.63
Best-Performing ETF Areas of Last Week
09:01am, Tuesday, 03'rd Dec 2024
Wall Street was upbeat last week with the Dow Jones and the S&P 500 hitting all-time highs last week.
The 3 Best Gene Editing Stocks to Buy in July 2024
09:00am, Monday, 08'th Jul 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. With the technology, we can fix faulty genes, or replace them with healthier gene
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
06:00am, Friday, 10'th May 2024
Genomics is the future of medicine. With it, companies are racing to shed light on human health and disease.
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
06:04am, Thursday, 02'nd May 2024
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.
GNOM: Genomics Still Waiting For Its 'ChatGPT' Moment
03:49pm, Friday, 22'nd Mar 2024
GNMO invests across companies benefiting from advancements in the field of genomics within biotechnology. The fund's historical performance has been poor amid volatile stock prices for underlying hold
3 Stocks That Could Be the Next Big Thing in Gene Editing
04:19pm, Thursday, 21'st Mar 2024
Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.
3 Gene Editing Stocks With Unprecedented Surge Potential
06:05am, Tuesday, 13'th Feb 2024
Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
12:28pm, Wednesday, 31'st Jan 2024
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
VettaFi Voices On: The Outlook for 2024
03:08pm, Friday, 08'th Dec 2023
Good morning, VettaFi Voices! We are a week out from the VettaFi 2024 Market Outlook Symposium on December 14, which will feature a range of ETF industry leaders discussing their expectations for diff
3 Gene Editing Stocks to Generate Super-Charged Gains
11:05am, Wednesday, 18'th Oct 2023
Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia,
Healthcare Dashboard For August And Focus On GNOM
08:15am, Monday, 14'th Aug 2023
This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value a
